Tesamorelin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-28 and is reviewed periodically as new material appears.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
The tunica media (Neo-Latin "middle coat"), or media for short, is the middle tunica (layer) of an artery or vein. It lies between the internal elastic lamina of the tunica intima on the inside and the tunica externa on the outside.
MIL-53 MOFs possess a "wine rack" structure. These MOFs have been explored for anisotropy in Young's modulus due to the flexibility of loading, and the potential for negative linear compressibility when compressing in one direction, due to the ability of the wine rack opening during loading.
Later, he served as the Republic's Minister of Justice. The first Grand Secretary of the new Grand Lodge was Aurelio Miranda Álvarez, who went by the Masonic codename Irving. The 1901 Constitution of Cuba, signed by many Freemasons, espoused many of the ideological views of the former GOCA and of the United Grand Lodge.
== World Accreditation Day (WAD) == NABL celebrates World Accreditation Day (WAD) every year on 9 June. World accreditation day is celebrated to provide awareness on accreditation and how accreditation benefits its stakeholders.
== Properties == N-Hydroxyphthalimide exists in two polymorphs, colorless and yellow, In the colorless white form, the NOH group is rotated about 1.19° from the plane of the molecule, while in the yellow form it is much closer to planarity (0.06° rotation). The color of the synthesized N-hydroxyphthalimide is determined by the solvent used; the color transition from white to yellow is irreversible. N-Hydroxyphthalimide forms strongly colored, mostly yellow or red salts with alkali and heavy metals, ammonia and amines. Hydrolysis of N-hydroxyphthalimide by the addition of strong bases produces phthalic acid monohydroxamic acid by adding water across one of the carbon–nitrogen bonds. N-Hydroxyphthalimide ethers, on the other hand, are colorless and provide O-alkylhydroxylamines by alkaline hydrolysis or cleavage through hydrazine hydrate. The "phthalylhydroxylamine" reported by Cohn was known to have a molecular formula of C8H5NO3, but the exact structure was not known. Three possibilities were discussed and are shown in the Figure below: a mono-oxime of phthalic anhydride ("phthaloxime", I), an expanded ring with two heteroatoms, (2,3-benzoxazine-1,4-dione, II), and N-hydroxyphthalimide (III). It was not until the 1950s that Cohn's product was definitely shown to be N-hydroxyphthalimide (III).
Sources: en.wikipedia.org
== Production and styles == Meat floss is made by stewing lean meat finely cut along the grain in a broth until the meat is very tender and individual muscle fibers can be teased apart. This happens when the water-insoluble collagen that holds the muscle fibers of the meat together has been converted into water-soluble gelatin. The meat is then separated from the broth and shredded into fibrous strips. It is then added back into the broth which is enriched with soy sauce, sugar, fennel, ginger, rice wine or other ingredients. The mixture is then cooked at low heat and stirred continuously until the floss is dried. There are different regional styles of meat floss, which differ in whether oil is added during the last process of production. Jiangsu style rousong is dry-cooked and the product is slightly chewy, while Fujian style bak hu is fried with oil and the product is mildly crispy. Five kilograms (11 lb) of meat will usually yield about one kilogram (2.2 lb) of floss. Taiwanese pork floss is made by cutting pork along the muscle fibers then boiling it for around 80 minutes to reduce moisture and soften collagen. The meat is then pressed into a paddle to loosen fibers, then transferred to a gas-fired frypan with mechanical scrapers to aid in drying and reducing the meat into long fibers. Sucrose, dehydrated starch and salt is then added at a specific time and ratio to enhance flavor and texture without hindering moisture removal. Once the desired consistency and dryness is obtained, the floss is stored briefly at room temperature and reheated in the scraping-frypan.
=== Repair phase === In the Repair phase, new tissue is generated which requires a balance of anti-inflammatory and pro-inflammatory eicosanoids. Anti-inflammatory eicosanoids include lipoxins, epi-lipoxins, and resolvins, which cause release of growth hormones.
A notable example is the calorimeter of the NA48 experiment at CERN containing about 27 tonnes of liquid krypton. This usage is rare, since liquid argon is less expensive. The advantage of krypton is a smaller Molière radius of 4.7 cm, which provides excellent spatial resolution with little overlapping. The other parameters relevant for calorimetry are: radiation length of X0=4.7 cm, and density of 2.4 g/cm3. Krypton-83 has application in magnetic resonance imaging (MRI) for imaging airways. In particular, it enables the radiologist to distinguish between hydrophobic and hydrophilic surfaces containing an airway. Although xenon has potential for use in computed tomography (CT) to assess regional ventilation, its anesthetic properties limit its fraction in the breathing gas to 35%. A breathing mixture of 30% xenon and 30% krypton is comparable in effectiveness for CT to a 40% xenon fraction, while avoiding the unwanted effects of a high partial pressure of xenon gas. The metastable isotope krypton-81m is used in nuclear medicine for lung ventilation/perfusion scans, where it is inhaled and imaged with a gamma camera. Krypton-85 in the atmosphere has been used to detect clandestine nuclear fuel reprocessing facilities in North Korea and Pakistan. Those facilities were detected in the early 2000s and were believed to be producing weapons-grade plutonium. Krypton-85 is a medium lived fission product and thus escapes from spent fuel when the cladding is removed. Krypton is used occasionally as an insulating gas between window panes.
The duplication events provided material for neofunctionalization to create the novel toxin genes, while gene loss influenced speciation and helped lead to such a wide variety of "chemical cocktails" in rattlesnake venoms. The prevailing theory for the driving force of this evolution is directional selection, where efficacy on prey is selected for. Diversity in prey leads to less specificity in toxins, while highly specialized toxins are more likely to develop when there are few key prey species. However, recently, balancing selection has been indicated to better explain the maintenance of adaptive genetic diversity in venom-related genes, potentially allowing for the rattlesnakes to better keep up in the evolutionary arms race with their prey. Older snakes possess more potent venom, and larger snakes are frequently capable of storing larger volumes of it.
Sources: en.wikipedia.org
=== End of the war === One month after Đien Bien Phu, the composite Groupe Mobile 100 (GM100) of the French Union forces evacuated the An Khê outpost. They were ambushed by a larger Viet Minh force at the Battle of Mang Yang Pass on 24 June and again at the Battle of Chu Dreh Pass on 17 July, suffering heavy losses. This was the last battle of the war, as the Geneva accords were signed four days later, and the final ceasefire took effect on 11 August 1954.
However, p21 can also be induced independently of p53 during processes such as differentiation, development, and in response to serum stimulation. p21 (WAF1) binds to cyclin-CDK complexes (notably CDK2, CDK1, CDK4, and CDK6), inhibiting their activity and blocking the G1/S transition. This inhibition enforces a cell cycle pause that allows DNA repair to occur. In cells with functional p53, p21 is upregulated in response to DNA damage, ensuring this checkpoint control. In contrast, p53 mutations impair p21 induction and compromise this control. In human embryonic stem cells (hESCs), although p21 mRNA is upregulated following DNA damage, the protein is not detectable. This reflects a nonfunctional p53-p21 axis at the G1/S checkpoint. This discrepancy is largely due to post-transcriptional repression, particularly by the miR-302 family of microRNAs, which inhibit p21 translation. Although p53 binds the CDKN1A promoter in hESCs, it does not regulate miR-302, which is constitutively expressed and suppresses p21 expression. The p53 pathway is interconnected with the RB1 pathway via p14^ARF, which links the regulation of these key tumor suppressors. p53 expression can be induced by UV radiation, which also causes DNA damage. In this context, p53 activation can initiate processes that lead to melanin production and tanning.
After World War II, it regained Northern Transylvania through the Paris Peace Treaties. Under Soviet occupation, King Michael I was forced to abdicate, and Romania became a socialist republic and Warsaw Pact member. After the fall of communism and the Romanian revolution in 1989, Romania transitioned to liberal democracy. Romania is a developed country with a high-income economy and is widely regarded as a middle power in international relations. The country possesses 11 UNESCO World Heritage Sites. Romania is a global net exporter of automotive parts and is an increasingly prominent technology centre with some of the fastest internet speeds in the world. Romania is a member of many international organizations, institutions, and forms of political and socio-economic cooperation, including: the UN since 1955, FAO since 1961, the Latin Union since 1980, the Council of Europe since 1993, the OSCE and OIF since 2003, NATO since 29 March 2004, the EU since 1 January 2007, the Schengen free-movement area toward the Occident since 1 January 2025, the EU–Mercosur free trade area since 2026, etc.; and of economic institutions: the World Bank Group, the IMF since 1972, the EBRD since 1991, the European Investment Bank since 2007, the Asian Infrastructure Investment Bank since 2018, etc.; and is a candidate for accession to the OECD.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.